SCHEMBL1016010

SCHEMBL1016010

C[C@@H](O)[C@H](O)[C@H](O)[C@H](C=O)OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BTN3A1 O00481 2/20 0.33
FDPS P14324 1/20 0.31
BLM P54132 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MPI P34949 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11305111 1.00 BTN3A1 (0.33) BTN3A1FDPSBLMTDP1MPI
SCHEMBL29512271 1.00 BTN3A1 (0.33) BTN3A1FDPSBLMTDP1MPI
SCHEMBL9698100 1.00 BTN3A1 (0.33) BTN3A1FDPSBLMTDP1MPI
Guanidine SCHEMBL9485722 0.92
SCHEMBL1976284 0.87 MPI (0.33) MPI
SCHEMBL7715581 0.87 MPI (0.33) MPI
SCHEMBL7715583 0.87 MPI (0.33) MPI
SCHEMBL6386404 0.81 MPI (0.34) MPI
SCHEMBL3492399 0.79 PGD (0.36)
SCHEMBL4082207 0.79 LMNA (0.37) BTN3A1TDP1MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214517-B2 α1,2-fucosyltransferase and DNA encoding the same KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-08 US claimed
EP-0642526-B1 PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE SCRIPPS RESEARCH INST (US) 1998-12-23 EP claimed
US-20260042866-A1 METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN GENENTECH, INC. (US) 2026-02-12 US disclosed
US-12391769-B2 Methods of making fucosylated and afucosylated forms of a protein GENENTECH, INC. (US) 2025-08-19 US disclosed
EP-4541815-A1 ANTIBODY AGAINST HEPATITIS B VIRUS, PREPARATION THEREOF AND USE THEREOF Huahui Health Ltd. (CN) 2025-04-23 EP disclosed
US-20240158536-A1 METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN GENENTECH, INC. (US) 2024-05-16 US disclosed
US-11802165-B2 Methods of making fucosylated and afucosylated forms of a protein GENENTECH, INC. (US) 2023-10-31 US disclosed
EP-2271669-A1 ANTIBODIES WITH ENHANCED ADCC FUNCTION Genentech, Inc. (US) 2011-01-12 EP disclosed
WO-2009114641-A1 ANTIBODIES WITH ENHANCED ADCC FUNCTION GENENTECH, INC. (US) 2009-09-17 WO disclosed
US-7335500-B2 Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose THE SCRIPPS RESEARCH INSTITUTE (US) 2008-02-26 US disclosed
US-20020068331-A1 Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose WONG CHI-HUEY (US) 2002-06-06 US disclosed
US-6319695-B1 FORMING A GLYCOSIDE BOND BY ETHERIFICATION AND CIRCULATION THE SCRIPPS RESEARCH INSITUTE 2001-11-20 US disclosed
EP-0642526-B1 PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE SCRIPPS RESEARCH INST (US) 1998-12-23 EP disclosed
EP-0642526-A4 PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. SCRIPPS RESEARCH INST (US) 1996-04-10 EP disclosed
EP-0642526-A1 PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE THE SCRIPPS RESEARCH INSTITUTE (US) 1995-03-15 EP disclosed
WO-1993008205-A1 PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE THE SCRIPPS RESEARCH INSTITUTE (US) 1993-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042866-A1 METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN FCGR2A, FCER2, FCGR3B BTN3A1 4357/4885FDPS 394/4885BLM 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.